טוען...
Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy
BACKGROUND: In Italy HPV vaccination with the quadrivalent vaccine (Gardasil(®)) is offered actively and free of charge to girls aged 12 since 2007. A nine-valent vaccine (Gardasil 9(®)) received the European market authorization in 2015 to protect, with only 2 doses, against around 90% of all HPV p...
שמור ב:
| הוצא לאור ב: | Cost Eff Resour Alloc |
|---|---|
| Main Authors: | , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5504713/ https://ncbi.nlm.nih.gov/pubmed/28701899 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12962-017-0073-8 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|